株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗生物質の世界市場:成長、動向、予測(2019〜2024年)

Antibiotics Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 391470
出版日 ページ情報 英文 116 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.97円で換算しております。
Back to Top
抗生物質の世界市場:成長、動向、予測(2019〜2024年) Antibiotics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年01月01日 ページ情報: 英文 116 Pages
概要

世界の抗生物質市場は、2018年に426億5,389万米ドル規模となりました。同市場は今後CAGR4.7%で拡大し、2024年には563億6,992万米ドルになると予測されています。

当レポートでは、世界の抗生物質市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場の定義動向

  • 市場概要
  • 市場促進因子
    • 抗MRSA/VRE薬の登場
    • ジェネリック薬の開発
    • 脆弱な高齢人人口
  • 市場阻害因子
    • 抗生物質への耐性
    • 積極的な研究に取り組む企業の少なさ
    • 法規制認可に要する時間
  • 業界の魅力度:ポーターズファイブフォース分析

第5章 市場セグメンテーション

  • 製品別
    • Cephalosporins
    • Penicillins
    • Fluroquinilones
    • Macrolides
    • Carbapenems
    • Aminoglycosides
    • Sulfonamides
    • その他
  • スペクトル別
    • 広域スペクトル抗生物質
    • 狭域スペクトル抗生物質
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合環境

  • 企業プロファイル
    • GlaxoSmithKline PLC
    • Johnson & Johnson Inc.
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Bayer Healthcare AG
    • Novartis AG
    • Sanofi SA
    • Abbott Laboratories
    • Roche Holding AG

第7章 市場の機会と将来動向

目次
Product Code: 49644

Market Summary

The global antibiotics market was valued at USD 42,653.89 million in 2018, and is estimated to be valued at USD 56,369.92 million in 2024, witnessing a CAGR of 4.7%. Certain factors that are driving the market growth include the emergence of anti-MRSA drugs, development of generic drugs, and vulnerable aging population.

A company that initially produced the patented drug tries to generate maximum revenue before the patent expires. Once the patent expires, there will be many competitors who begin manufacturing the generic formulations. They have the same composition and same pharmacological activities as of the original drug. Almost 80% of the prescription antibiotics are generic. As a result of this, the price is reduced. More people can afford drugs, thus, resulting in improved healthcare outcomes. However, indiscriminate drug usage also leads to drug resistance and other complications.

Scope of the Report

As per the scope of the report, antibiotic medicines are among the most prescribed courses worldwide, in fighting bacterial infections, primarily in outpatient settings.

Key Market Trends

Carbapenems are Expected to Show the Rapid Growth of in the Future.

The cephalosporin segment is expected to account for the largest market size during the forecast period. Carbapenems are expected to witness the highest CAGR of around 5.9% during the forecast period.

The rising threat of drug resistance and a weak pipeline of new molecules are leading to the development of combinational formulations. For instance, in countries, like India, the emergence of multi-drug-resistant tuberculosis (TB) is a major factor driving the R&D expenditures. Methicillin-resistant Staphylococcus aureus (MRSA) is another bacterium responsible for several infections in humans that are difficult to treat. The MRSA infection is difficult to treat with standard antibiotics, such as penicillins (methicillin, dicloxacillin, nafcillin, and oxacillin), and the cephalosporins. In 2014, the US Food and Drug Administration (FDA) approved four new antibiotics for the treatment of infections caused by gram-positive bacteria, including MRSA.

North America is Expected to Dominate the Market in the Forcasted Period

North America currently dominates the market for antibiotics and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increased adoption of antibiotics. The United States holds the majority of the market in the North American region, due to the fact that the United States has the highest antibiotic prescribing rate in the North American region. In addition, there is a rise in per capita health expenditure in the country, which is expected to increase over the forecast period, owing to decrease in the unemployment rate.

Competitive Landscape

The antibiotics market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence, by introducing new products with less prices. Companies, like Glaxosmithkline, Pfizer PLC, Bayer AG, Novartis AG, and Abbott Inc., hold significant market shares in the antibiotics market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Emergence of Anti-MRSA/VRE Drugs
    • 4.2.2 Development of Generic Drugs
    • 4.2.3 Vulnerable Aging Population
  • 4.3 Market Restraints
    • 4.3.1 Antibiotic Resistance
    • 4.3.2 Fewer Companies Involved in Active Research
    • 4.3.3 Time Taken for Regulatory Approval
  • 4.4 Industry Attractiveness of Porter's Five Forces Analysis

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Cephalosporins
    • 5.1.2 Penicillins
    • 5.1.3 Fluroquinilones
    • 5.1.4 Macrolides
    • 5.1.5 Carbapenems
    • 5.1.6 Aminoglycosides
    • 5.1.7 Sulfonamides
    • 5.1.8 Other Product Types
  • 5.2 By Spectrum
    • 5.2.1 Broad-spectrum Antibiotics
    • 5.2.2 Narrow-spectrum Antibiotics
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 France
      • 5.3.2.2 Germany
      • 5.3.2.3 United Kingdom
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 GlaxoSmithKline PLC
    • 6.1.2 Johnson & Johnson Inc.
    • 6.1.3 Merck & Co. Inc.
    • 6.1.4 Pfizer Inc.
    • 6.1.5 Bayer Healthcare AG
    • 6.1.6 Novartis AG
    • 6.1.7 Sanofi SA
    • 6.1.8 Abbott Laboratories
    • 6.1.9 Roche Holding AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top